In recent years, the immunotherapy represented by PD-1/PD-L1 immune checkpoint inhibitors has changed the current situation of anti-tumor treatment in NPC.2, 12 A two-arm study total of 67 patients with recurrent and metastatic NPC were sorted into anti-PD1 inhibitor and chemotherapy group and anti-PD1 inhibitor only group, and reported that adding chemotherapy to anti-PD1 inhibitor significantly improved 6 month PFS and OS for NPC patients.13 This evidence concerns the gene CD274 and nasopharyngeal carcinoma.